Ardeshir Ghavamzadeh

Ardeshir Ghavamzadeh

Auto-generated profile, based on publicly available information

Ardeshir Ghavamzadeh

Hematology, Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, Tehran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2023 in Nanomedicine
Verified
Journal Article
Closed access
ZHZahra Sadat Hashemi
Zahra Sadat Hashemi
MGMahlegha Ghavami
Mahlegha Ghavami
Seyed hossein KiaieSeyed hossein Kiaie
Seyed hossein Kiaie
FMFateme Mohammadi
Fateme Mohammadi
MBMahdieh Shokrollahi Barough
Mahdieh Shokrollahi Barough
RFRamin Sarrami Forooshani
Ramin Sarrami Forooshani
Aim: We investigated the delivery of sorafenib (SFB) to breast cancer spheroids by natural killer cell-derived exosomes (NK-Exos). Methods: SFB-NK-Exos were constructed by electroporation. Their an... Plain language summary What is this summary about? This study describes the delivery of an anticancer drug called sorafenib (SFB) to laboratory-grown spherical masses of cancer cells called spheroi...

26 April 2004 in Transfusion
Verified
Journal Article
Closed access
PDF file
MBM.A. Mohyeddin Bonab
M.A. Mohyeddin Bonab
KAK.A. Alimoghaddam
K.A. Alimoghaddam
ZGZahra Goliaei
Zahra Goliaei
AGA.R. Ghavamzadeh
A.R. Ghavamzadeh

5 May 2013 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
SHSaeed Hassani
Saeed Hassani
SGSeyed H. Ghaffari
Seyed H. Ghaffari
FZFarhad Zaker
Farhad Zaker
RMRohellah Mirzaee
Rohellah Mirzaee
HMHajar Mardani
Hajar Mardani
AGArdeshir Ghavamzadeh
Ardeshir Ghavamzadeh

1 September 2017 in Anti-Cancer Drugs
Verified
Journal Article
Closed access
PDF file
AZAli Zekri
Ali Zekri
YMYashar Mesbahi
Yashar Mesbahi
SGSamad Ghanizadeh-Vesali
Samad Ghanizadeh-Vesali
KAKamran Alimoghaddam
Kamran Alimoghaddam
AGArdeshir Ghavamzadeh
Ardeshir Ghavamzadeh
SGSeyed H. Ghaffari
Seyed H. Ghaffari
Aurora-B kinase overexpression plays important roles in the malignant progression of prostate cancer (PCa). AZD1152-HQPA, as an inhibitor of Aurora-B, has recently emerged as a promising agent for cancer treatment. In this study, we aimed to investigate the effects of AZD1152-HQPA on reactive oxygen species (ROS) generation and mitochondrial function in PCa. We used AZD1152-HQPA (Barasertib), a highly potent and selective inhibitor of Aurora-B kinase. The effects of AZD1152-HQPA on cell viability, DNA content, cell morphology, and ROS production were studied in the androgen-independent PC-3 PCa cell line. Moreover, the mitochondrial copy number and the expression of genes involved in cell survival and cancer stem cell maintenance were investigated. We found that AZD1152-HQPA treatment induced defective cell survival, polyploidy, micronuclei formation, cell enlargement, and cell death by significant overexpression of p73, p21 and downregulation of cell cycle-regulatory genes in a drug concentration-dependent manner. Moreover, AZD1152 treatment led to an excessive ROS generation and an increase in the mitochondrial copy number not only in PC-3 but also in several other malignant cells. AZD1152 treatment also led to downregulation of genes involved in the maintenance of cancer stem cells. Our results showed a functional relationship between the aurora kinase inhibition, an increase in mitochondrial copy number, and ROS generation in therapeutic modalities of cancer. This study suggests that the excessive ROS generation may be a novel mechanism of cytotoxicity induced by the aurora kinase inhibitor, AZD1152-HQPA.

1 March 2012 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
Amir Ali HamidiehAmir Ali Hamidieh
Amir Ali Hamidieh
MKMona Kargar
Mona Kargar
MJMohammad Jahani
Mohammad Jahani
KAKamran Alimoghaddam
Kamran Alimoghaddam
BBBabak Bahar
Babak Bahar
AGArdeshir Ghavamzadeh
Ardeshir Ghavamzadeh
The most widely accepted conditioning regimen to allogeneic hematopoietic stem cell transplantation consists of total body irradiation, especially in patients affected by acute lymphoblastic leukemia (ALL). In this retrospective study, we report our experience on hematopoietic stem cell transplantation in 44 pediatric patients with acute lymphoblastic leukemia using a non-radiation–based conditioning regimen (busulfan/cyclophosphamide). Median age at transplantation was 12.5 years (range, 4 to 14 y). 39 out of 44 patients received transplants in complete remission. At a median follow-up of 390 days, the probabilities of 3-year disease-free survival and overall survival were 50% and 68%, respectively. Disease status of hematopoietic stem cell transplantation was the only significant variable affecting the overall survival. Acute and chronic graft-versus-host disease occurred in 23 (64%) and 12(18%) patients, respectively. Relapse was significantly higher among patients transplanted in advanced disease status. The results of the study indicate that non-radiation–based preparative regimens can be used in pediatric patients with ALL. However, well-designed comparative trials are needed to better clarify the difference between radiation and non-radiation–based conditioning regimens in pediatric ALL.

27 June 2018 in Journal of Oncology Pharmacy Practice
Verified
Journal Article
Closed access
HMHamidreza Taghvaye Masoumi
Hamidreza Taghvaye Masoumi
MHMolouk Hadjibabaie
Molouk Hadjibabaie
KGKheirollah Gholami
Kheirollah Gholami
MZMorvarid Zarif-Yeganeh
Morvarid Zarif-Yeganeh
AGArdeshir Ghavamzadeh
Ardeshir Ghavamzadeh
Voriconazole is extensively metabolized by the CYP450 isoenzymes 2C19 and 3A4 and to a lesser extent by CYP2C9; therefore, any medication that affects this pathway can alter its plasma concentration. Treatment failure can probably occur if subtherapeutic levels are achieved. A 32-year-old woman who suffered from acute lymphoblastic leukemia was admitted and received treatment with vincristine and dexamethasone. After several days, to control her fever, based on two consecutive positive serum galactomannan test results, voriconazole as an antifungal agent was added to Aspergillus infection treatment. Through the first week after voriconazole initiation, its plasma concentrations were subtherapeutic. The most suspicious medication for interaction was dexamethasone, which can induce CYP450 isoenzymes and reduce plasma concentration. As a result of the narrow therapeutic window of voriconazole and the relationship between efficacy and plasma concentration of azoles, therapeutic drug monitoring of voriconazole in patients receiving a high dose of glucocorticoids is recommended, in order to achieve optimal response to treatment and toxicity reduction. Further studies regarding the interaction between voriconazole and dexamethasone to prevent clinically relevant interactions should be considered.